Combination	ClinicalTrials.gov Identifier	Combination	ClinicalTrials.gov Identifier
Target therapy and checkpoint blockade		Targeted Therapy and Cytokine Therapy
Dabrafenib+/Trametinib+lpilimumab	(NCT01767454;NCT01940809; NCT01673854;NCT02200562)	Vemurafenib+High-dose IL-2	(NCT01754376; NCT01683188)
Nivolumab + Wunitinib, Pazopanib, or Ipilimumab	(NCT01472081)	Vemurafenib+IL-2 (infusional 96 hour)+IFN-α	(NCT01603212)
Dabrafenib+Trametinib followed by Ipilimumab+Nivolumab or vice versa	(NCT02224781)	Vemurafenib+Pegylated IFN	(NCT01959633)
Vemurafenib+Anti−PD-Ll	(NCT01656642)	Nilotinib+ Peginterferon α2b	(NCT01657604; NCT01866553; NCT02001818; NCT01220648)
Dabrafenib+Trametinib+Anti−PD-1	(NCT02130466)	Vemurafenib+High-dose IFN-α2b	(NCT01943422)
Trametinib+/− Dabrafenib+Anti−PD-    L1	(NCT02027961)	Pegylated IFN-alpha 2B+ Dasatinib	(NCT01725204; NCT01872442)
Imatinib mesylate+lpilimumab	(NCT01738139)
lpilimumab+Cetuximab+/− Intensity-    Modulated Radiation Therapy	(NCT01935921)
Sunitinib +Nivolumab	(NCT02400385)
Pembrolizumab +Axitinib in    advanced RCC	(NCT02133742)
Dasatinib+lpilimumab	(NCT01643278)
Targeted Therapy and Cytokine Therapy
Vemurafenib+Tumor-infiltrating Lymphocytes	(NCT00338377; NCT01585415; CT01659151)
Dasatinib+DC vaccine	(NCT01876212)
Vaccine-peptide derived from the protein IDO (IDO Long)+lpilimumab+ vemurafenib)	(NCT02077114)
Cetuximab+ GVAX+ Cyclophosphamide	(NCT00305760)